Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deflazacort. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.94 |
| ▸ | PGR | P06401 | 7/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deflazacort SCHEMBL4019 | 0.97 | NR3C1 (1.00) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL24497637 | 0.97 | NR3C1 (1.00) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL2598076 | 0.97 | NR3C1 (1.00) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL4018 | 0.97 | NR3C1 (1.00) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL22502722 | 0.96 | NR3C1 (0.98) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL4259541 | 0.95 | NR3C1 (0.95) | NR3C1PGRHIF1ANR1I2CNR1 | |
| SCHEMBL13653579 | 0.90 | NR3C1 (0.86) | NR3C1PGRHIF1ANR1I2CNR1 | |
| Deflazacort SCHEMBL887173 | 0.89 | NR3C1 (0.84) | NR3C1PGRHIF1ANR1I2LMNA | |
| 21-Desacetyldeflazacort SCHEMBL30754690 | 0.87 | NR3C1 (0.81) | NR3C1PGRHIF1ANR1I2CNR1 | |
| SCHEMBL13653592 | 0.86 | NR3C1 (0.80) | NR3C1PGRHIF1ANR1I2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107532201-B | Method for assessing response of patients with ataxia telangiectasia to glucocorticoid therapy | 爱瑞德勒股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| US-10619208-B2 | Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment | ERYDEL S.P.A. (IT) | 2020-04-14 | — | — | US | claimed |
| EP-3247805-B1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | Erydel Spa (IT) | 2019-03-27 | — | — | EP | claimed |
| US-20180016637-A1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | QUINCE THERAPEUTICS, INC. | 2018-01-18 | — | — | US | claimed |
| CN-107532201-A | The method for assessing reaction of the patient of ataxia telangiectasia to glucocorticoid treatment | 爱瑞德勒股份有限公司 | 2018-01-02 | — | — | CN | claimed |
| EP-3247805-A1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | EryDel S.p.A. (IT) | 2017-11-29 | — | — | EP | claimed |
| WO-2016116850-A1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | ERYDEL S.P.A. (IT) | 2016-07-28 | — | — | WO | claimed |
| CN-107532201-B | Method for assessing response of patients with ataxia telangiectasia to glucocorticoid therapy | 爱瑞德勒股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-10619208-B2 | Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment | ERYDEL S.P.A. (IT) | 2020-04-14 | — | — | US | disclosed |
| EP-3247805-B1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | Erydel Spa (IT) | 2019-03-27 | — | — | EP | disclosed |
| US-20180016637-A1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | QUINCE THERAPEUTICS, INC. | 2018-01-18 | — | — | US | disclosed |
| EP-3247805-A1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | EryDel S.p.A. (IT) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016116850-A1 | METHOD OF EVALUATING THE RESPONSE OF ATAXIA TELANGIECTASIA PATIENTS TO GLUCOCORTICOIDS TREATMENT | ERYDEL S.P.A. (IT) | 2016-07-28 | — | — | WO | disclosed |
| CN-101410120-A | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES INC (US) | 2009-04-15 | — | — | CN | disclosed |